CARLSBAD, Calif.–(BUSINESS WIRE)—- $LCTX #AMD–Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing novel cell therapies for unmet medical needs, announced today that it will report its se…
Author: Business Wire
Aerie Pharmaceuticals to Announce Second Quarter 2020 Financial Results and Host Conference Call on Thursday, August 6, 2020
DURHAM, N.C.–(BUSINESS WIRE)–Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucom…
Kubota Vision Demonstrates 3D Imaging Capabilities Using AI on PBOS
SEATTLE–(BUSINESS WIRE)–Kubota Vision Inc. (“Kubota Vision”), a clinical-stage ophthalmology company and wholly-owned subsidiary of Kubota Pharmaceutical Holdings Co., Ltd. (Tokyo 4596), today announced that the company demonstrated 3D imaging capabi…
IVERIC bio to Report Second Quarter 2020 Financial Results and Host Conference Call on Wednesday, August 5, 2020
NEW YORK–(BUSINESS WIRE)–IVERIC bio today announced that it will report its second quarter 2020 financial and operating results on Wednesday, August 5, 2020.
Nura Bio Launches to Discover and Develop Neuroprotective Drugs, Backed by $73 Million Series A Financing
SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–Nura Bio Inc., a biopharma company created to discover and develop life-changing neuroprotective drugs, today announced its official launch. Alpna Seth, PhD, a leader in the global biotechnology industry, i…
AlphaGroup Medical Communications celebrates 15th anniversary of AlphaBioCom while simultaneously launching AlphaScientia, AlphaQsci
KING OF PRUSSIA, Pa.–(BUSINESS WIRE)– #AlphaGroup–AlphaGroup scientific and medical communications agencies announces 15-year anniversary of AlphaBioCom and launch of AlphaScientia and AlphaQsci.
On-Demand Health Care Provider Remedy Names Dr. Ronald Dixon Chief Medical Officer
AUSTIN, Texas–(BUSINESS WIRE)– #RemedyUrgentCare–Remedy, an on-demand health care provider, today named veteran health tech executive Dr. Ronald Dixon as chief medical officer to support the expansion of Remedy’s 24/7 medical services, including pro…
Seoul Semiconductor’s SunLike Series Natural Spectrum LEDs Adopted by Traditional Japanese Brand for Children’s Room Lighting to Support Students’ Learning and Concentration
ANSAN, South Korea–(BUSINESS WIRE)– #ChildrenRoomLighting–Seoul Semiconductor’s SunLike Series natural spectrum LEDs have been adopted by Koizumi for use in lights for children’s rooms and living rooms.
ソウル半導体、健康と学習をサポートする太陽光スペクトルLED “SunLike”をシーリングライト向けに供給
韓国安山市–(BUSINESS WIRE)– #SunLike–Seoul Semiconductorは太陽光スペクトルLEDの”SunLike”を照明器具メーカーのコイズミ照明株式会社の新製品となるリビング、子供部屋向けのシーリングライトに供給している。…
Global Eyeglasses Market Outlook and Forecast 2020-2027 – ResearchAndMarkets.com
DUBLIN–(BUSINESS WIRE)–The “Eyeglasses – Global Market Trajectory & Analytics” report has been added to ResearchAndMarkets.com’s offering. The publisher brings years of research experience to this 19th edition of the report. The 589-page report p…
Global Ophthalmology Devices Market Analysis Highlights the Impact of COVID-19 2020-2024 | Increasing Prevalence of Ophthalmic Diseases to Boost Market Growth | Technavio
LONDON–(BUSINESS WIRE)– #GlobalOphthalmologyDevicesMarket–The Global Ophthalmology Devices Market will grow by $ 13.03 bn during 2020-2024
jCyte Inc. Announces Promising Phase 2b Results of jCell Therapy in Retinitis Pigmentosa
NEWPORT BEACH, Calif.–(BUSINESS WIRE)–jCyte Inc. Announces Promising Phase 2b Results of jCell Therapy in Retinitis Pigmentosa
4D Molecular Therapeutics Announces First Patient Dosed in Phase 1 Clinical Trial of 4D-110 by Intravitreal Injection for the Treatment of Choroideremia
EMERYVILLE, Calif.–(BUSINESS WIRE)–4D Molecular Therapeutics (4DMT), a clinical-stage leader in the development of precision-guided AAV gene medicines based on directed evolution, announced that the first patient has been dosed in the Phase 1 clinica…
NovaBay Pharmaceuticals to Hold Second Quarter 2020 Conference Call on August 6
EMERYVILLE, Calif.–(BUSINESS WIRE)– #Avenova–NovaBay Pharmaceuticals to Hold Second Quarter 2020 Conference Call on August 6
Global Contact Lenses Market Growth and Trends by Product Type, Usage, Modality, Design and Region – Forecast to 2025 – ResearchAndMarkets.com
DUBLIN–(BUSINESS WIRE)–The “Contact Lenses Market – Growth, Trends, and Forecasts (2020-2025)” report has been added to ResearchAndMarkets.com’s offering. The growth of the global contact lens market is due to the increasing prevalence of optical dis…
2020 Pipeline Database for Ophthalmology – ResearchAndMarkets.com
DUBLIN–(BUSINESS WIRE)–The “Ophthalmology Pipeline Database – 2020” report has been added to ResearchAndMarkets.com’s offering. This report provides the most up-to-date information on key pipeline products in the global Ophthalmology Drug market. It …
Ocular Therapeutix Announces Second Medicare Administrative Contractor to Establish New Published Physician Fee Schedule for Administration of Intracanalicular Inserts
BEDFORD, Mass–(BUSINESS WIRE)—- $OCUL #OCUTX–Ocular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today an…
National Vision Holdings, Inc. Announces Second Quarter 2020 Earnings Release and Conference Call
DULUTH, Ga.–(BUSINESS WIRE)–National Vision Holdings, Inc. (NASDAQ: EYE) (“National Vision” or the “Company”) will report its second quarter 2020 financial results before the market opens on Thursday, August 6, 2020. The Company will host a conferenc…
Aurinia Prices US$200 Million Public Offering of Common Shares
VICTORIA, British Columbia–(BUSINESS WIRE)–Aurinia Prices US$200 Million Public Offering of Common Shares
Phase III Data Show Port Delivery System With Ranibizumab Enabled Over 98% of Patients to Go Six Months Between Treatments for Neovascular Age-Related Macular Degeneration
SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY) today announced detailed results from the Phase III Archway study evaluating its investigational Port Delivery System with ranibizumab (PD…